Melinda Gooderham, MD, is a dermatologist and the medical director at the SKiN Centre for Dermatology.

Melinda Gooderham, MD, MSc, medical director of the SKiN Centre for Dermatology in Peterborough, Ontario, discussed 

Alopecia areata remains a chronic, immune-mediated condition with limited systemic treatment options, and ritlecitinib is currently the only therapy approved for adolescent patients, leaving a clear need for additional effective treatments across age groups. Gooderham said this unmet need helped shape the rationale behind evaluating upadacitinib in a broad population that included both adults and adolescents with severe disease.

How Much Hair Regrowth Did Upadacitinib Achieve in Severe Alopecia Areata?

What Was the Design of the UP-AA1 and UP-AA2 Trials?

UP-AA1 and UP-AA2 were 2 replicate, global, randomized, double-blinded, placebo-controlled phase 3 trials designed to confirm efficacy findings across independent patient populations. The trials enrolled adolescents and adults ages 12 to younger than 64 years with severe alopecia areata, defined as a Severity of Alopecia Tool (SALT) score of 50 or greater, reflecting at least 50% scalp hair loss. Patients were randomized in a 2:2:1 ratio to receive 15 mg upadacitinib, 30 mg upadacitinib, or placebo once daily.

The primary 24-week double-blinded treatment period, referred to as period A, was followed by a 28-week blinded extension period. The primary end point was achievement of a SALT score of 20 or less, corresponding to at least 80% scalp hair coverage, at Week 24. Secondary end points included eyebrow and eyelash outcome measures, earlier SALT score improvements at weeks 4, 8, and 12, achievement of a SALT score of 10 or less, complete hair regrowth (SALT score of 0), and patient-reported quality of life and global impression of change measures.

What Did the Trial Results Show About Hair Regrowth?

Gooderham explained that patients had a mean baseline SALT score of 84, corresponding to roughly 16% scalp hair coverage. At week 24, the primary end point of SALT score 20 or less was achieved by 45% of patients receiving the 15-mg dose and 55% of patients receiving the 30-mg dose, compared with just 1% to 3% of patients receiving placebo.

She noted that a SALT score of 10 or less, corresponding to 90% scalp coverage, was achieved by approximately one-third of patients on the 15-mg dose and half of patients on the 30-mg dose. Gooderham said this level of regrowth carries meaningful clinical significance, since patients reaching 80% to 90% scalp coverage can typically style their hair, reduce reliance on wigs or head coverings, and no longer have hair loss as the most visible feature to others.

Editor’s note: Gooderham’s has previously reported non-financial support from Takeda in addition to personal fees from AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Meiji, Dermavant, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx, and Apogee.

Mostaghimi A, Gooderham MJ, Lynde C, et al. Upadacitinib for severe alopecia areata in adults and adolescents: two phase 3 UP-AA randomized clinical trials. JAMA Dermatol. Published online August 12, 2026. 

Smith T. UP-AA: Upadacitinib Attains Primary Endpoint in New Alopecia Areata Data. HCPLive. August 13, 2026. Accessed August 19, 2026. 

https://www.hcplive.com/view/up-aa-upadacitinib-attains-primary-endpoint-alopecia-areata-data

Videos

Melinda Gooderham, MD, MSc, discusses new JAMA data on upadacitinib's efficacy for severe alopecia areata in adults and adolescents.

Alopecia

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Abivax announced positive topline results from Part 2 of the phase 3 ABTECT maintenance trial evaluating obefazimod in ulcerative colitis (UC), showing clinically meaningful efficacy through week 44 in patients who did not initially respond to induction therapy. 

The data build on positive Part 1 topline results announced in early June, when both the 25 mg and 50 mg doses of obefazimod met the primary endpoint of clinical remission and all key secondary endpoints.

Remo Panaccione, MD, professor of medicine and director of the IBD Clinic at the University of Calgary, discussed the ABTECT maintenance program, obefazimod's safety profile, and where the drug could fit into an increasingly crowded UC treatment landscape in an interview with HCPLive.

Part 2 Builds on Part 1's Placebo-Adjusted Efficacy

In Part 2 of the maintenance trial, patients receiving continuous treatment with the 50 mg dose achieved the strongest outcomes across key clinical and endoscopic endpoints, further strengthening obefazimod's benefit-risk profile ahead of the company's planned new drug application (NDA) submission in the fourth quarter of 2026. The long-term safety profile remained consistent with previous studies, with no new safety signals observed.

Part 1 of the maintenance study included 580 patients who had initially responded to induction therapy and then entered the randomized, placebo-controlled maintenance study. Part 2 enrolled an additional 633 patients who had either not responded during induction or had subsequently lost response during maintenance, a population that included the largest cohort of patients with an inadequate response to a JAK inhibitor studied in a phase 3 UC trial to date.

Both the 25 mg and 50 mg doses met the primary endpoint of clinical remission, with remission rates of approximately 51% with either active dose compared with 10% with placebo, a 40-point placebo-adjusted difference

Endoscopic remission, defined as a Mayo endoscopy score of 0 or 1 among patients who entered the trial with a score of 2 or 3, was achieved by 41.5% of patients on 25 mg and 47.7% of patients on 50 mg, compared with 10% on placebo

Both doses also met all key secondary endpoints, including endoscopic improvement, histologic-endoscopic mucosal improvement, and steroid-free remission

Among initial non-responders who continued on the 50 mg dose, about 37% achieved clinical remission and more than 60% achieved response

Among patients who relapsed on the 25 mg dose during maintenance and were escalated to 50 mg, clinical remission was recaptured in about 56%

Q&A: Remo Panaccione, MD, on the ABTECT Maintenance Program

You've had the opportunity to review the complete ABTECT maintenance program. What do you see as the biggest takeaway for clinicians treating patients with moderate to severe ulcerative colitis?

Before we talk about the maintenance part, it's important to recognize that these results are building upon very impressive induction data, where we saw placebo-adjusted treatment differences for the primary endpoint of clinical remission that were quite substantial. Importantly, the onset of benefit of this drug, which is a once-a-day oral, was rapid, with separation from placebo as early as week one for symptomatic response and week two for symptomatic remission.

Moving into the maintenance part, there are several takeaways. First, this is a very large, clinically relevant program. Part one of the maintenance study included 580 patients who had initially responded to induction and then entered the randomized, placebo-controlled maintenance study. Part two included an additional 633 patients who had either not responded during induction or had subsequently lost response during maintenance.

It's also important for clinicians to recognize that this study included a substantial portion of patients who were difficult to treat. In particular, it enrolled the largest cohort of patients with an inadequate response to a JAK inhibitor that we've ever studied in a phase 3 clinical trial. That's particularly important because JAK inhibitor use tends to be later-line therapy, and we know those patients don't respond as well as naive patients or patients exposed only to monoclonal antibodies.

In part one, there were two maintenance doses, 25 mg and 50 mg, and both met the primary endpoint of clinical remission at week 44. Remission rates were quite high, approximately 51% with either active dose compared to only 10% with placebo. That 40-point difference is the largest placebo-adjusted difference we've seen in a phase 3 trial. Part of that may be due to the placebo rate being quite low, which usually reflects a difficult-to-treat patient population.

In part two, among initial non-responders who continued on 50 mg, about 37% achieved remission and over 60% achieved response. Among patients who relapsed on 25 mg during maintenance and were escalated to 50 mg, clinical remission was recaptured in about 56%.

The most compelling data, though, is the objective data, endoscopic and histologic. All patients entered the trial with a Mayo endoscopy score of 2 or 3, moderate to severe endoscopic inflammation, and needed to reach a score of 0 or 1 to achieve remission. In part one, endoscopic remission was 41.5% with 25 mg and 47.7% with 50 mg, compared to only 10% with placebo. These are among the strongest endoscopic remission results we've seen in a phase 3 program. Both doses also met all key secondary endpoints, including endoscopic improvement, histologic-endoscopic mucosal improvement, and steroid-free remission. And over 44 weeks, we didn't see any safety signals that were concerning.

The maintenance data also substantially expanded the long-term safety database. How would you characterize the safety profile of obefazimod at this stage of development, and what gives you confidence in its benefit-risk profile?

I think the safety looks quite good. When the induction data was first released publicly, there were a few malignancies in the 50 mg dose, and I think that was a little bit misinterpreted. When interpreting rare safety events like malignancy, it's important not to focus solely on raw numbers. These events were uncommon, and simple case counts can be misleading, particularly when treatment exposure differs across groups.

With maintenance, we have more exposure, and that gives us a better picture of safety. The 50 mg group had the greatest cumulative treatment exposure and included many of the most treatment-refractory patients. When patients receive a treatment for longer, we'd naturally expect more events in that group. So the important thing is to look at exposure-adjusted incidence rates rather than raw counts.

Across both the phase 2 and phase 3 programs, there's over 1,700 patient-years of exposure. Rates of things like non-melanoma skin cancer are consistent with published malignancy rates in ulcerative colitis. There was a prostate cancer and a breast cancer in the 50 mg dose, but those aren't rare cancers, and they occurred in patients where we'd expect them. The available data doesn't suggest a dose-dependent malignancy signal with obefazimod. We have phase 2 data going out beyond four years now, and when you weigh the benefit against what we're seeing for safety, it's a very favorable benefit-risk profile.

Ulcerative colitis has become an increasingly crowded treatment landscape with numerous advanced therapies available. Based on the totality of the ABTECT data, where do you envision obefazimod fitting into clinical practice if it's approved?

You're absolutely right that it's becoming a crowded landscape. Whenever a new molecule comes into the clinic, we need to ask what it really brings to the table compared to what we already have. Here, we have a once-daily oral small molecule with a different mechanism of action than anything currently available in the clinic. That mechanism is intriguing to us because it increases expression of miR-124, a naturally occurring microRNA, which brings the immune system back into balance rather than acting as a true immunosuppressant like some of the therapies we currently have.

Editors' note: Panaccione has relevant disclosures with Abbott, AbbVie, Abivax, Alimentiv, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead Sciences, Janssen, Merck, Novartis, Pfizer, Takeda, and others.

Abivax announces landmark Phase 3 ABTECT maintenance trial results evaluating obefazimod in moderately to severely active ulcerative colitis. News release. Abivax. June 1, 2026. Accessed August 19, 2026. 

https://www.globenewswire.com/news-release/2026/06/01/3304711/0/en/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-obefazimod-in-moderately-to-severely-active-ulcerative-colitis.html

Abivax reports positive ABTECT maintenance Part 2 results for obefazimod, demonstrating meaningful clinical benefit in refractory ulcerative colitis patients and strengthening the Phase 3 maintenance safety database. News release. Abivax. June 29, 2026. Accessed August 19, 2026. 

https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results/

Articles

Abefazimod demonstrated durable, clinically meaningful maintenance efficacy through week 44 in moderate-to-severe ulcerative colitis, including patients failing induction or losing response. Across 25 mg and 50 mg dosing, clinical remission approached 51% versus 10% with placebo, alongside robust endoscopic and histologic endpoints and steroid-free remission. In refractory subsets, continued 50 mg converted ~37% of induction nonresponders to remission, while dose escalation from 25 mg to 50 mg recaptured remission in ~56%. Safety remained consistent, supported by >1,700 patient-years and no new signals.

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC

Associate Professor of Medicine and an attending physician in the Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology & Allergy at UCLA. He also serves as director of the Pharmaceutical Policy & Outcomes Lab.

In an emulated target trial using nationwide health claims data, patients with 

chronic obstructive pulmonary disease (COPD)

 who started maintenance azithromycin had a lower risk of moderate or severe exacerbations than those started on roflumilast, according to William B. Feldman, MD, MPH, PhD, a pulmonologist and health services researcher at UCLA Health. Feldman told HCPLive the analysis, published in 

, drew on Optum Clinformatics claims data from March 2011 to August 2024 and centered on a primary analysis of 7550 propensity-score-matched pairs.

“This was a target trial emulation where we used a large longitudinal healthcare claims database to ask the question of whether we see different clinical outcomes in patients with COPD who receive azithromycin versus roflumilast,” Feldman said, noting both drugs are approved to prevent exacerbations but had never been compared head-to-head. He said the study, pre-registered on the Open Science Framework, used propensity score matching across a range of covariates, along with sensitivity analyses, to limit confounding inherent to observational data. Results are also expected soon from RELIANCE, an ongoing randomized controlled trial directly comparing the 2 therapies; Feldman said his findings are meant to complement, not substitute for, that trial.

William Feldman, MD: Azithromycin Over Roflumilast in Real World COPD Data

In a secondary analysis restricted to the 2454 patients who met RELIANCE's inclusion and exclusion criteria, propensity matching yielded 714 pairs, and azithromycin was again associated with a lower risk of first all-cause hospitalization or death (hazard ratio, 0.83; 95% CI, 0.72-0.95; number needed to treat, 15; 95% CI, 9-46) compared with roflumilast.

 Feldman said prespecified subgroup analyses, including by prior COPD hospitalization and eosinophil count, showed broadly consistent treatment effects, an important distinction now that biologic therapies are available for patients with elevated eosinophils who would not otherwise be candidates for azithromycin or roflumilast.

How should clinicians interpret the findings?

Feldman was careful to flag the study's limits. The analysis measured only exacerbation risk, not safety: azithromycin carries known risks of QT prolongation and hearing changes, while roflumilast is more commonly associated with gastrointestinal side effects, neither of which was captured in the claims data. Follow-up time was also shorter than ideal, he said, since many patients discontinued therapy before the 1 to 2 years he would have preferred to observe.

Feldman said the findings are meant to help guide treatment decisions while clinicians and patients await RELIANCE's results. “In COPD, we don’t get a lot of new therapies that hit the market,” he said. “So I think really drilling down into the kind of optimal treatment algorithms with therapies that we have is quite important.”

Feldman WB, et al. Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial. 

 2026;394:e100111. doi:10.1136/bmj-2026-100111

Krishnan JA, Holbrook JT, Sugar EA, et al. Rationale and design of the roflumilast or azithromycin to prevent COPD exacerbations clinical trial. 

 2026;13(1):17-28. doi:10.15326/jcopdf.2025.0669

Nationwide claims-based target trial emulation compared maintenance azithromycin versus roflumilast for COPD exacerbation prevention using Optum Clinformatics data (2011–2024). In 7550 propensity-score–matched pairs, azithromycin initiation was associated with lower risk of moderate or severe exacerbations. A RELIANCE-eligible subset (714 matched pairs) similarly favored azithromycin for first all-cause hospitalization or death (HR 0.83; NNT 15). Interpretation is constrained by observational confounding, limited follow-up due to discontinuation, and lack of captured safety outcomes.

Feldman, of UCLA Health, discusses a target trial emulation finding azithromycin outperformed roflumilast at preventing COPD exacerbations.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Joshua Remick, MD, is a cardiologist with Providence Health & Services.

Although guidelines and therapies have made significant advancements in recent years, 

 care still regularly contends with adherence issues, access to treatment, and more of the same barriers it has faced for decades.

Improving Heart Failure Care for All, With Joshua Remick, MD

Joshua Remick, MD, a cardiologist with Providence Health & Services, joined 

 recently to moderate a clinical forum titled “Getting to the Heart of the Matter: Recognition to Treatment Optimization of Heart Failure.” In this post-forum interview, Remick breaks down the progress heart failure therapy has made in the past years, as well as highlighting where more momentum is needed.

“I think one of the things that we’ve learned most about heart failure management is that patients benefit the sooner they get on therapy and the quicker they get titrated up on appropriate therapies,” Remick told 

. “Because these therapies also impact other disease states like renal function, endocrine function, and cardiac care in general, these patients end up having interactions with multiple different specialties. The sooner all of these specialty providers feel comfortable getting patients on appropriate medical therapy, it’s going to benefit our patient population.”

Multidisciplinary care has been a cornerstone of cardiovascular care in recent years, given the rich interplay between the cardiovascular, endocrine, and other systems. In 2022, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America released clinical guidelines explicitly recommending a multidisciplinary team, citing its capacity to reduce hospitalization rates and healthcare costs while improving self-care adherence and the use of guideline-directed medical therapy (GDMT).

The guidelines proposed a collaboration between cardiologists, surgeons, psychologists, immunologists, dieticians, clinical pharmacists, advanced practice providers, physical therapists, and more, aiming to address every possible facet of both immediate and long-term patient care. Remick expresses his support for this model.

However, despite these clear indications, heart failure treatment still faces lingering roadblocks. Among the most prevalent of these is the large-scale difficulty for both patients and clinicians in adopting and persisting with GDMT. Typical treatment begins with the simultaneous initiation of 4 medications, including beta-blockers, mineralocorticoid receptor agonists, SGLT2 inhibitors, and ARNIs or ACE inhibitors. Each drug addresses an individual component of heart failure risk, and as such, clinicians are advised to prescribe all 4 to a given patient.

However, several studies have highlighted the significant pill burden that this places on patients, particularly in situations when patients are unaware of the importance of quadruple therapy. Additionally, the financial burden posed by these 4 separate prescriptions is, in some situations, a substantial barrier to adherence – ARNIs and SGLT2 inhibitors in particular tend to rack up particularly burdensome costs.

In addressing this, Remick discussed the need for further patient education to drive home the importance of all 4 medications working in unison. He also acknowledged that, until action is taken on a large scale to shift all patients onto optimal GDMT, the negative outcomes that have positioned heart failure among the most fatal diseases in the US cannot significantly improve.

“A lot of times, we prescribe these drugs in patients who are doing quite well and living daily lives without major limitations and symptoms, so it’s a hard sell to try and get them to take more drugs, especially those that are associated with a fair amount of cost,” Remick said. “And so, especially in the US with the cost of healthcare, it’s really challenging to get all of that on board and get patients willing to do what’s needed.”

Editors’ Note: Remick reports no relevant disclosures.

Sokos G, KIDO K, PANJRATH G, et al. Multidisciplinary Care in heart failure services. 

Philbin SE, Gleason LP, Persell SD, et al. Barriers and Facilitators to Heart Failure Guideline-Directed Medical Therapy in an Integrated Health System and Federally Qualified Health Centers: A Thematic Qualitative Analysis. 

Remick discusses multidisciplinary teams, adherence issues, and the path forward for heart failure care in this post-forum interview.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Symptoms and inflammation do not always move together in inflammatory bowel disease (IBD), and for Jordan Axelrad, MD, MPH, co-director of NYU Langone's Inflammatory Bowel Disease Center, that disconnect shapes nearly every conversation he has with patients who call in feeling unwell.

"Symptoms do not always correlate with objective inflammatory activity," Axelrad told HCPLive in an interview.

Check Out More of Our Interview With Axelrad 

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH

Patients often reach out reporting acute symptoms and asking for prednisone, assuming a flare is underway. Axelrad said it's important for patients to understand that a symptom flare doesn't always line up with actual disease activity, which is exactly why an objective check is needed before assuming the worst.

"That may require laboratories, biomarkers including C-reactive protein and fecal calprotectin, it may require endoscopy to more objectively assess the status of the mucosa, and in patients with Crohn's disease, may often require cross-sectional radiography or intestinal ultrasound," he said. The specific combination depends on the patient, but the goal is the same across the board: replace a subjective symptom report with objective evidence before deciding how to act on it.

"Having these objective markers of inflammatory activity help us differentiate symptom exacerbation or an infectious etiology from flare of underlying IBD," Axelrad said. Those distinctions, he noted, are managed very differently.

"I have the treat-to-target conversation with all of my patients so that my patients and I are on exactly the same page when we're discussing therapy initiation," Axelrad said. That means setting expectations up front: symptomatic improvement within a couple of weeks to months, biomarker improvement on a similar timeline, and longer-term endoscopic, or in Crohn's disease sometimes radiographic, improvement as the ultimate target.

"Generally we want to see meaningful improvements in endoscopic response within 6 months to 1 year, and we're adjusting treatment based on treat-to-target if we're not achieving those important goals," he said.

"There may be instances where patients have no response to an individual therapy, in which case we may switch to a completely different mechanism, whereas many patients may have partial response and we may work towards optimizing that therapy to meet our treat-to-target goals," Axelrad said. That variability is precisely why the objective checkpoints matter: without them, a partial responder and a non-responder can look identical from the symptom picture alone.

Counseling Patients as a Physician Who Has Crohn's Disease

"I think patients find comfort in recognizing that I'm someone who's also used the medications that I'm talking about with patients," Axelrad said. He lives with Crohn's disease himself, and said that for a disease that often affects younger people, moving to a long-term infusion or injectable therapy is a major modification to a patient's life. That shared experience shapes what he listens for in a visit, since patients rarely lead with questions about how fast a drug works.

"Patients oftentimes don't come to the office saying, how quickly can I feel better? They're usually much more concerned about the side effect profile and the long-term interruption of these medications in their lives," he said.

Having sat on the other side of that conversation himself, Axelrad said he's able to meet those concerns directly rather than defaulting to reassurances about efficacy alone.

"Having that personal experience I think really gives patients calm and more confidence in making these decisions together as far as medication selection," Axelrad said.

Editor’s Note: Axelrad reports relevant disclosures with AbbVie, Abivax, Adiso, BioFire Diagnostics, bioMérieux, Bristol Myers Squibb, and others. 

National Institute of Diabetes and Digestive and Kidney Diseases. Crohn's disease. NIDDK. Reviewed July 2024. Accessed August 18, 2026. 

https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease

Crohn's & Colitis Foundation. What are the early indicators of Crohn's disease and ulcerative colitis, and how are these two diseases different from each other? Crohn's & Colitis Foundation. Accessed August 18, 2026. 

https://www.crohnscolitisfoundation.org/blog/ulcerative-colitis-vs-crohns-disease-what-are-the-early-signs-and-how-are-they-diagnosed

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Strategic Alliance Partnership

Brian Vickery, MD, chief of allergy and immunology at Children's Healthcare of Atlanta.

Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Q&A: Inside the First-in-Human Peanut Allergy Microneedle Stamp Trial

Robert Sarkany, MD, FRCP, is a consultant dermatologist at St John's Institute of Dermatology at Guy's and St Thomas' Hospital in London and at the Lister Hospital.

Robert Sarkany, MD, FRCP, discusses PORT-77's phase 2a safety profile in EPP and the endpoints to watch as the drug advances to phase 2b/3.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

What Comes Next for PORT-77 as It Heads Toward Phase 2b/3?

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The first-in-class D1 receptor antagonist earns Priority Review and Orphan Drug designation, with an FDA action date late in Q1 2027.

FDA News

Pediatrics

Pediatrics page, resources on the topics of medical news and expert insight into childhood health care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on pediatric disease research, treatment, and drug development.

Neurology

Neurology condition center page is a comprehensive resource for clinical news and insights on nervous system disorders. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for Alzheimer's disease, brain injury, PTSD, and more.

FDA Accepts NDA for Ecopipam in Pediatric Tourette Syndrome

Investigators outline how phase 1 safety data could inform a phase 2 efficacy study and eventual pediatric enrollment down to age 4 years.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Microneedle Peanut Allergy Trial Charts Path to Pivotal Testing

In this interview, Robert Sarkany, MD, FRCP, explains the biology behind erythropoietic protoporphyria and how PORT-77 targets its underlying cause.

How ABCG2 Inhibition Could Change EPP Disease Management

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH

The first-in-human study is testing an ascending-dose microneedle device designed to deliver peanut protein through the skin in just 3 minutes.

Microneedle Stamp Enters Phase 1 Trial for Peanut Allergy Immunotherapy

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH

Philippe Genereux, MD, is the co-director of the Structural Heart Disease Program at Atlantic Health Morristown Medical Center.

Philippe Généreux, MD, discusses a secondary analysis of EARLY TAVR examining patients excluded from the trial for positive treadmill stress tests.

Structural Heart Disease

Treadmill Stress Tests Safe, Reliable for Detecting Severe Asymptomatic Aortic Stenosis

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Latest News

How Much Hair Regrowth Did Upadacitinib Achieve in Severe Alopecia Areata?

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC

William Feldman, MD: Azithromycin Over Roflumilast in Real World COPD Data

Improving Heart Failure Care for All, With Joshua Remick, MD

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH